Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NYP3
UPID:
DONS_HUMAN
Alternative names:
B17
Alternative UPACC:
Q9NYP3; Q8NC53; Q9NSR9; Q9NVZ5; Q9NYP1; Q9NYP2
Background:
Protein downstream neighbor of Son, also known as B17, plays a crucial role in maintaining genome stability. It acts as a replisome component that protects stalled or damaged replication forks. This protein is essential for the stabilization of replication forks under stress, activation of cell-cycle checkpoints, and overall genome integrity.
Therapeutic significance:
B17 is linked to severe disorders like Microcephaly-micromelia syndrome and Microcephaly, short stature, and limb abnormalities, both involving growth restrictions and skeletal dysplasia. Understanding the role of B17 could open doors to potential therapeutic strategies for these genetic conditions.